Nonalcoholic fatty liver disease in type 2 diabetes mellitus

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 2, 2009, Pages 141-149

  Cusi, Kenneth ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Insulin resistance; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pioglitazone; Rosiglitazone; Steatosis; Thiazolidiendiones; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BIOLOGICAL MARKER; FATTY ACID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOSARTAN; METFORMIN; OLMESARTAN; OMEGA 3 FATTY ACID; PIOGLITAZONE; ROSIGLITAZONE; TELMISARTAN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ADIPOSE TISSUE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DYSLIPIDEMIA; EARLY DIAGNOSIS; FATTY LIVER; GLUCOSE BRAIN LEVEL; GOLD STANDARD; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATIENT SAFETY; REVIEW; TREATMENT RESPONSE; WEIGHT REDUCTION; ANIMAL; LIVER; METABOLISM; PATHOLOGY; RISK FACTOR;

ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; RISK FACTORS;

EID: 66149088144     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283293015     Document Type: Review

References (112)

1. Ali R, Cusi K. New diagnostic and treatment approaches in nonalcoholic fatty liver disease (NAFLD). Ann Med 2009. [Epub ahead of print]. http://dx.doi.org/10.1080/07853890802552437 Comprehensive overview of the risk factors for the development of NASH with emphasis on future diagnostic and treatment approaches.
2. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.Curr Diab Rep 2007; 7:175-180. Detailed review about the close relationship in patients with diabetes between NASH, cirrhosis and hepatocellular carcinoma.
3. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51:1947-1953. Review assessing the cluster of cardiovascular risk factors associated with NAFLD and the specific risk associated with the presence of fatty liver.
4. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19:1564-1570.
5. Baumeister SE, Völzke H, Marschall P, et al. Impact of fatty liver disease on healthcare utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134:85-94.
6. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-1395.
7. Chen J, Mathew M, Finch J, Cusi K. The prevalence of NAFLD in T2DM is highest among Hispanics and is closely related to hepatic and adipose tissue insulin resistance [abstract]. Diabetes 2009; 58 (Suppl 1).
8. Targher G, Lorenzo B, Roberto P, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30:1212-1218.
9. Leite N, Salles G, Araujo A, Villela-Nogueira C, Cardoso C. Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29:113-119.
10. Mofrad P. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37:1286-1292.
11. Sorrentino P. Silent nonalcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004; 41:751-757.
12. Amarapurkar D, Patel N. Clinical spectrum and natural history of nonalcoholic steatohepatitis with normal alanine aminotransferase values. Trop Gastroenterol 2004; 25:130-134.
13. Fracanzani A, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48:792-798. Valuable study in a large cohort of patients with NASH about the possibility of significant liver disease in NASH even in the presence of normal liver transaminases.
14. Maheshwari A, Paul JT. Cryptogenic cirrhosis and NAFLD: are they related? Am J Gastroenterol 2006; 101:664-668.
15. Caldwell S, Lee V. Cryptogenic cirrhosis. AASLD Postgraduate Course 2008; 2008:48-57. State-of-the-art review on cryptogenic cirrhosis and its frequent association with obesity and T2DM.
16. Ekstedt M, Franzén L, Mathiesen U, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-873.
17. A-Kader H, Henderson J, Vanhoesen K, et al. Nonalcoholic fatty liver disease in children: a single center experience. Clin Gastroenterol Hepatol 2008; 6:799-802.
18. Schwimmer J. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis 2007; 27:312-318.
19. Schwimmer J, Pardee P, Lavine J, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118:277-283. Highlights the early development of cardiovascular risk factors in children with NAFLD.
20. Demircioglu F, Kocyigit A, Arslan N, et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatric Gastroenterol Nutr 2008; 47:68-75.
21. Harrison S, Oliver D, Arnold H, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57:1441-1447. Valuable examination of risk factors in a large population of patients with NAFLD.
22. Cusi K. Evolving concepts in lipotoxicity. AASLD Postgraduate Course 2008; 2008:72-84.
23. Perseghin G, Lattuada G, De Cobelli F, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47:51-58.
24. Zib I, Jacob A, Lingvay I, et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med 55:ePub (electronic version); 2007.
25. Mehta SR, Thomas EL, Bell JD, et al. Noninvasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14:3476-3483.
26. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297-2307.
27. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133:496-506.
28. Poynard T, Ratziu V, Charlotte F, et al., and the LIDO study group, and the CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006; 6:34.
29. Ratziu V, Massard J, Charlotte F, et al., and the LIDO study group, and the CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006; 6:6.
30. Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-854.
31. Wieckowska A, McCullough A, Feldstein A. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46:582-589. Excellent review on the current role and future potential of plasma biomarkers for the management of NAFLD and NASH.
32. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960-974. Comprehensive review on the role of this imaging technique from the available literature.
33. Castera L, Forns X, Alberti A. Noninvasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
34. Wieckowska A, McCullough A, Feldstein A, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44:27-33.
35. Yoneda M, Mawatari H, Fujita K, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digest Liver Dis 2008; 40:371-378.
36. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48:442-448. The following (ref. [37-42]) are all outstanding reviews by leaders in the field on the mechanisms that lead to NAFLD and NASH
37. Pessayre D. Role of mitochondria in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22:S20-S27.
38. Elsharkawy A, Mann D. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007; 46:590-597.
39. Greenfield V, Cheung O, Sanyal A. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008; 24:320-327.
40. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008; 19:295-300.
41. Li Z, Berk M, McIntyre TM, et al. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008; 47:1495-1503.
42. Marra F, Gastaldelli A, Svegliati Baroni G, et al. Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med 2008; 14:72-81.
43. Wei Y, Wang D, Topczewski F, Pagliassotti M. Fructose-mediated stress signaling in the liver: implications for hepatic insulin resistance. J Nutr Biochem 2007; 18:1-9.
44. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J Hepatol 2008; 48:993-999.
45. Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Digest Dis Sci 2007; 52:589-593.
46. Ryan MC, Abbasi F, Lamendola C, et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 2007; 30:1075-1080.
47. Adiels M, Taskinen M-R, Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diabetes Rep 2008; 8:60-64. Excellent review on the topic.
48. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134:1369-1375.
49. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351.
50. Stefan N, Peter A, Cegan A, et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008; 51:648-656.
51. Vinciguerra M, Veyrat-Durebex C, Moukil MA, et al. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 2008; 134:268-280.
52. Qiu W, Federico L, Naples M, et al. Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins. Hepatology 2008; 48:1799-1809.
53. Minehira K, Young SG, Villanueva CJ, et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res 2008; 49:2038-2044.
54. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46:1081-1090. Provocative study on the role of different types of lipids in the development of NASH using novel techniques in the field.
55. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48:474-486.
56. Mari M, Colell A, Morales A, et al. Mechanism of mitochondrial glutathionedependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 2008; 134:1507-1520.
57. Gentile C, Pagliassotti M. The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease. Curr Opin Investig Drugs 2008; 9:1084-1088.
58. Listenberger L, Han X, Lewis S, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003; 100:3077-3082.
59. Wu X, Zhang L, Gurley E, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18 beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008; 47:1905-1915.
60. Wang S, Kamat A, Swamy A, et al. Hepatic steatosis is associated with mitochondrial dysfunction in obese and diabetic rats [abstract]. Diabetes 2008; 55 (Suppl 1). Study dissecting the role of FFA, glucose, and insulin in the induction of mitochondrial dysfunction in rodent models of NAFLD.
61. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294:G1281-G1287.
62. Mark N, deAlwis W, Day C. Genes and nonalcoholic fatty liver disease. Curr Diabetes Rep 2008; 8:156-163. Comprehensive review on the different genes reported to be involved in the development of NAFLD.
63. Musso G, Gambino R, De Michieli F, et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 2008; 47:1167-1177.
64. Tomita K, Oike Y, Teratani T, et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 2008; 48:458-473.
65. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100.
66. Zhou M, Xu A, Tam PK, et al. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 2008; 48:1087-1096.
67. Ding X, Saxena NK, Lin S, et al. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166:1655-1669.
68. Wang R, Koretz R, Yee H. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003; 115:554-559.
69. Harrison S, Day C. Benefits of lifestyle modification in NAFLD. Gut 2007; 56:1760-1769. Excellent review on the topic.
70. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48:449-457.
71. Sjostrom L, Narbro K, Sjostrom CD, et al., the Swedish Obese Subjects S. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752.
72. de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2008; 11:267-274.
73. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effects of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22:222-226.
74. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39:770-778.
75. Dufour JF, Oneta CM, Gonvers JJ, et al., and the Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537-1543.
76. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis [see comment]. Am J Gastroenterol 2003; 98:2485-2490.
77. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2:1107-1115.
78. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119-128.
79. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:2365-2368.
80. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4:639-644.
81. Harrison S, Fecht W, Brunt E, Neuschwander-Tetri B. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49:80-86.
82. Kurita S, Takamura T, Ota T, et al. Olmesartan ameliorates a dietary rat model of nonalcoholic steatohepatitis through its pleiotropic effects. Eur J Pharmacol 2008; 588:316-324.
83. Yokohama S, Tokusashi Y, Nakamura K, et al. :. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate activation in nonalcoholic steatohepatitis. World J Gastroenterol 2006; 12:322-326.
84. Enjoji M, Kotoh K, Kato M, et al. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int J Mol Med 2008; 22:521-527.
85. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45:1375-1381.
86. Jin H, Yamamoto N, Uchida K, et al. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2007; 364:801-807.
87. Uno M, Kurita S, Misu H, et al. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology 2008; 48:109-118
88. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for nonalcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther 2006; 24:698-699.
89. Argo K, Loria P, Caldwell S, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008; 48:662-669.
90. Riley P, Sudarshi D, Johal M, et al. Weight loss, dietary advice and statin therapy in nonalcoholic fatty liver disease: a retrospective study. Int J Clin Pract 2008; 62:374-381.
91. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31:384-1384.
92. Vega G, Chandalia M, Szczepaniak L, Grundy S. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med 2008; 56:780-785.
93. Merat S, Aduli M, Kazemi R, et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Digest Dis Sci 2008; 53:2246-2250.
94. Cusi K, DeFronzo R. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6:89-131.
95. Marchensini G, Bianchi G, Tomassetti S, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 348:893-894.
96. Uygun A, Kadayifci A, Isik A, et al. Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19:537-544.
97. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100:1082-1090.
98. Lingvay I, Raskin P, Szczepaniak L. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007; 21:137-142.
99. de Oliveira C, Stefano J, de Siqueira E, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with nonalcoholic steatohepatitis. Hepatol Res 2008; 38:159-165.
100. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Therap 2008; 30:1168-1176.
101. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53:2169-2176.
102. Mathew M, Ali R, Kumar P, et al. Intensive insulin therapy reduces hepatic steatosis and improves insulin secretion in T2DM [abstract]. Diabetes 2009; 58 (Suppl 1).
103. Mendoza C, Ali R, Mathew M, et al. Replacement of premeal insulin for exenatide reduces hepatic steatosis and improves insulin secretion in patients with T2DM [abstract]. Diabetes 2009; 58 (Suppl 1).
104. Cusi K. Thiazolidinediones for the treatment of nonalcoholic steatohepatitis (NASH). Exp Rev Gastroenterol Hepatol 2009; (in press). Comprehensive review on the mechanisms and potential role of TZDs for the management of NASH.
105. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am JGastroenterol 2001; 96:519-525.
106. Neuschwander-Tetri BA, Brunt EM, Kent R, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-g ligand rosiglitazone. Hepatology 2003; 38:1008-1017.
107. Serfaty L. Pioglitazone: the beginning of a new era for NASH? J Hepatol 2007; 47:160-162.
108. Lang L. Pioglitazone trial for NASH: results show promise. Gastroenterology 2007; 132:836-838.
109. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135:1176-1184. A 12-month RCT of pioglitazone in NASH showing a significant effect on metabolic parameters, insulin sensitivity, and histological variables such as liver injury and fibrosis.
110. Balas B, Belfort R, Harrison S, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with nonalcoholic steatohepatitis. J Hepatol 2007; 47:565-570.
111. Ratziu V, Giral P, Jacqueminet S, et al., Group TLS. Rosiglitazone for NASH: one year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135:100-110. A 12-month RCT of rosiglitazone in NASH showing a significant effect on liver transaminases, insulin resistance, and steatosis.
112. Ratziu V, Charlotte F, Bernhard C, et al. Long-term efficacy of rosiglitazone in NASH: results of the extension phase of the FLIRT-2 trial. Hepatology 2008; 48:803A.